Adma Biologics (ADMA) Change in Account Payables (2011 - 2025)

Adma Biologics' Change in Account Payables history runs 13 years deep, the most recent figure standing at -$2.2 million for Q4 2025.

• Quarterly Change in Account Payables fell 155.89% year-over-year to -$2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.3 million (down 43.86% YoY) and the FY2025 annual result came in at $2.3 million, down 43.86% from the prior year.
• Change in Account Payables was -$2.2 million for Q4 2025 at Adma Biologics, up from -$4.9 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $13.8 million in Q3 2022 and bottomed at -$12.0 million in Q4 2022.
• A 5-year average of $623750.0 and a median of $66000.0 in 2023 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2024 — Change in Account Payables surged 16280.0% — and 2025, when it sank 401.36%.
• Adma Biologics' Change in Account Payables stood at -$4.9 million in 2021, then sank by 146.61% to -$12.0 million in 2022, then jumped by 141.73% to $5.0 million in 2023, then decreased by 21.07% to $3.9 million in 2024, then tumbled by 155.89% to -$2.2 million in 2025.
• Business Quant data shows ADMA's Change in Account Payables at -$2.2 million in Q4 2025, -$4.9 million in Q3 2025, and $9.3 million in Q2 2025.